According to the business intelligence report titled, ‘Global Dengue Testing Market Size study, by Product Type (ELISA-Based Tests, RT-PCR Based Tests, Dengue IgG/IgM Rapid Test, Others) by End User (Hospitals, Diagnostic Centers, Others) and Regional Forecasts 2021-2027’, available with MarketStudyReport, global dengue testing market is expected to record a y-o-y growth rate of 4.74% during 2021-2027 and amass a valuation of USD 630.28 Mn by the forecast period-end.
 

Conclusive findings by experts imply that the change in climate due to global warming and an increase in the number of infected people in highly populated nations has led to a rise of the global dengue testing market.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4219589/
 

As per WHO, the number of dengue cases has surged from 2.4 Mn in 2010 to 5.2 Mn in 2019, indicating a high need for the testing product.
 

However, inconsistent efforts by the government to eradicate this disease may impede the growth trajectory in the aforementioned timeline.
 

For the uninitiated, Dengue is a mosquito-borne viral disease that is mainly prevalent in tropical and sub-tropical areas.
 

Moving on to the segmental analysis, the marketplace is fragmented on the basis of product type and end-user respectively. Based on the product, the industry is further divided into ELISA-based test, RT-PCR rapid test, and dengue IgG/IgM test among others. Speaking of the end-user scope, the business sphere is classified into hospitals and diagnostic centers among others.
 

From a regional frame of reference, the scope of the global dengue testing market is majorly defined by North America, Europe, Asia Pacific, and Latin America. Asia Pacific captures significant market share owing to suitable climatic conditions for dengue vector, high exposure to DENV virus, and presence of low- and middle-income countries. Partnerships among key players and increasing awareness programs by governments are enhancing regional market development.
 

Europe is also likely to serve as a strong growth avenue as the changing climate in colder European countries has increased dengue outbreaks.
 

Key players in the industry are Thermo Fisher Scientific Inc., Abnova, F. Hoffman-La Roche AG, OriGene Technologies, Euroimmun, DiaSorin, Abbot Laboratories, Certest Biotec SL. NovaTec Immundiagnostica GmBH, and InBios International, Inc.